These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Flower MA; al-Saadi A; Harmer CL; McCready VR; Ott RJ Eur J Nucl Med; 1994 Jun; 21(6):531-6. PubMed ID: 8082669 [TBL] [Abstract][Full Text] [Related]
3. Thyroid imaging using positron emission tomography--a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis. Flower MA; Irvine AT; Ott RJ; Kabir F; McCready VR; Harmer CL; Sharma HL; Smith AG Br J Radiol; 1990 May; 63(749):325-30. PubMed ID: 2198979 [TBL] [Abstract][Full Text] [Related]
4. [F-qi-FDG PET of the thyroid gland in Graves' disease]. Börner AR; Voth E; Wienhard K; Wagner R; Schicha H Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612 [TBL] [Abstract][Full Text] [Related]
5. The Sonographic Features of the Thyroid Gland After Treatment with Radioiodine Therapy in Patients with Graves' Disease. English C; Casey R; Bell M; Bergin D; Murphy J Ultrasound Med Biol; 2016 Jan; 42(1):60-7. PubMed ID: 26603660 [TBL] [Abstract][Full Text] [Related]
6. Comparison of methods for thyroid volume estimation in patients with Graves' disease. van Isselt JW; de Klerk JM; van Rijk PP; van Gils AP; Polman LJ; Kamphuis C; Meijer R; Beekman FJ Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):525-31. PubMed ID: 12541136 [TBL] [Abstract][Full Text] [Related]
7. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography. Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H Thyroid; 1998 Sep; 8(9):765-72. PubMed ID: 9777746 [TBL] [Abstract][Full Text] [Related]
8. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414 [TBL] [Abstract][Full Text] [Related]
9. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167 [TBL] [Abstract][Full Text] [Related]
10. Fully automated computer-aided volume estimation system for thyroid planar scintigraphy. Huang JY; Lin KJ; Chen YS Comput Biol Med; 2013 Oct; 43(10):1341-52. PubMed ID: 24034725 [TBL] [Abstract][Full Text] [Related]
11. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease. Sawicka N; Sowiński J Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091 [TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554 [TBL] [Abstract][Full Text] [Related]
13. Measurement of radiation dose to the thyroid using positron emission tomography. Ott RJ; Batty V; Webb BS; Flower MA; Leach MO; Clack R; Marsden PK; McCready VR; Bateman JE; Sharma H Br J Radiol; 1987 Mar; 60(711):245-51. PubMed ID: 3494482 [TBL] [Abstract][Full Text] [Related]
14. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease. Markovic V; Eterovic D J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305 [TBL] [Abstract][Full Text] [Related]
15. Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves' disease for evaluation of active inflammation. Uslu-Beşli L; Kabasakal L; Sağer S; Cicik E; Asa S; Sönmezoğlu K Nucl Med Commun; 2017 Nov; 38(11):964-970. PubMed ID: 28863123 [TBL] [Abstract][Full Text] [Related]
16. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Howarth D; Epstein M; Lan L; Tan P; Booker J Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491 [TBL] [Abstract][Full Text] [Related]
17. Low-activity 124I-PET/low-dose CT versus 99mTc-pertechnetate planar scintigraphy or 99mTc-pertechnetate single-photon emission computed tomography of the thyroid: a pilot comparison. Darr AM; Opfermann T; Niksch T; Driesch D; Marlowe RJ; Freesmeyer M Clin Nucl Med; 2013 Oct; 38(10):770-7. PubMed ID: 23877506 [TBL] [Abstract][Full Text] [Related]
18. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease). Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064 [TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656 [TBL] [Abstract][Full Text] [Related]
20. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Peters H; Fischer C; Bogner U; Reiners C; Schleusener H Eur J Clin Invest; 1996 Jan; 26(1):59-63. PubMed ID: 8682157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]